Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of orantinib (TSU-68) with S-1 and oxaliplatin in metastatic colorectal cancer
jRCT2080221365Phase 1
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orantinib in metastatic colon cancer (mCRC) and colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of orantinib (TSU-68) in combination with S-1 and oxaliplatin and Pharmacokinetics of orantinib (TSU-68) in combination with S-1 and oxaliplatin.
02
Drugs
orantinib
03
Conditions
metastatic colon cancer (mCRC)colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2080221365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221365.